|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.180 USD | 0.00% |
|
-8.73% | -42.02% |
Summary: Altimmune, Inc.
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Altimmune, Inc.
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Altimmune, Inc.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings Chart: Altimmune, Inc.
Source: Surperformance
ESG chart: Altimmune, Inc.
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| - | - | 339M | |||
| 34.18B | |||||
| 31.87B | |||||
| 14.15B | |||||
| 13.8B | |||||
| 13.02B | |||||
| 12.02B | |||||
| Average | 17.05B | ||||
| Weighted average by Cap. |
Investor (Composite)
-
Trader (Composite)
ESG MSCI
BBB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
-
Net Margin
-
Financial Health (Composite)
-
Valuation
P/E
-
EV/Revenue
EV/EBITDA
-
PBR
Dividend Yield
-
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALT Stock
- Ratings Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition